Action LSB LAKESHORE BIOPHARMA CO., LTD
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues LakeShore Biopharma Co., Ltd

Actions

LSB

KYG9845F1090

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 14/06/2024 		Varia. 5j. Varia. 1 janv.
0,6977 USD +0,93% Graphique intraday de LakeShore Biopharma Co., Ltd -8,20% +36,54%
10/06 Lakeshore Biopharma Co. annonce des changements au sein de sa direction CI
28/05 YS Biopharma Co, Ltd. changera son symbole boursier de YS à LSB CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
LakeShore Biopharma : Departure of Directors Form 6 K
Lakeshore Biopharma Co., Ltd Announces Executive Changes
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS
YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28
YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Results of Extraordinary General Meeting
YS Biopharma Co., Ltd. Approves Board Appointments
YS Biopharma Co., Ltd. has Changed its Name to LakeShore Biopharma Co., Ltd
Ys Biopharma Co., Ltd Announces Executive Changes
YS Biopharma Co., Ltd. Approves the Appointment of Hui Shao as the Chief Business Officer
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LSB
  4. Actualités LakeShore Biopharma Co., Ltd
  5. Autres langues